Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BE1116 (4-Factor PCC) in traumatic injury with major bleeding
NCT05568888Phase 3Terminated
- Sponsor
- CSL Limited
- Start
- Mar 2023
- Primary completion
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
A Phase 3 trial of balfaxar in traumatic injury, sponsored by CSL Limited. Started Mar 2023; status: terminated.
02
Drugs
balfaxar
03
Conditions
traumatic injury
Beyond the preview
Go deeper on NCT05568888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05568888.